Iodopol

Sodium Iodide, the active ingredient in Iodopol, is a radioactive iodine compound presented as an oral solution for oral use. It is employed in the diagnosis and treatment of thyroid disorders, including cancer and hyperfunctioning conditions.

GNH USA supplies Iodopol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets. The product meets European Union pharmacopeia standards and is manufactured under strict GMP conditions.

Iodopol, containing sodium iodide‑131, is used in therapeutic and diagnostic pathways related to thyroid tissue.

- Thyroid cancer: facilitates ablation of residual thyroid tissue after thyroidectomy. - Hyperthyroidism: reduces hormone production by delivering targeted radiation to overactive thyroid cells. - Thyroid imaging: enables visualization of functional thyroid tissue distribution for diagnostic assessment. - Thyroid nodules: assists in functional evaluation to differentiate benign from malignant lesions. - Metastatic thyroid cancer: helps detect iodine‑avid metastatic disease throughout the body.

Sodium Iodide‑131 may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring shortly after administration. - Dry mouth: reduced salivary flow leading to discomfort. - Taste alteration: transient metallic taste sensation. - Neck pain: mild discomfort in the thyroid region. - Transient hypothyroidism: temporary reduction in thyroid hormone levels. - Mild leukopenia: slight decrease in white blood cell count.

Serious or Rare Side Effects: - Bone marrow suppression: significant reduction in blood cell production. - Severe hypothyroidism: prolonged deficiency requiring hormone replacement. - Allergic reaction: rash, itching, or anaphylaxis in rare cases. - Radiation thyroiditis: inflammation of the thyroid gland. - Pulmonary fibrosis: rare scarring of lung tissue following high cumulative doses.

When using Iodopol, several precautions should be observed to ensure safety and efficacy. - Pregnancy: avoid unless benefits outweigh risks, due to fetal radiation exposure. - Breastfeeding: contraindicated, as iodine‑131 can be secreted in milk. - Renal impairment: monitor renal function and adjust monitoring frequency. - Thyroid function: assess baseline thyroid status before therapy. - Radiation safety: follow strict handling and disposal protocols to protect staff and public. - Store at ambient temperature: keep in original container, protect from light and moisture.

Sodium Iodide‑131 can interact with certain medications and substances that affect iodine uptake or radiation response.

Major Interactions (Avoid): - Antithyroid drugs (propylthiouracil, methimazole): block iodine uptake, reducing efficacy. - Lithium: decreases thyroid uptake of iodine, diminishing therapeutic effect. - Amiodarone: high iodine content may interfere with radioiodine distribution.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal excretion of iodine‑131, requiring monitoring. - Chemotherapy agents: can increase risk of bone marrow suppression when combined.